These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacogenomic modeling in pancreatic cancer—letter. Avan A; Avan A; Maftouh M; Mobarhan MG; Gholamin S Clin Cancer Res; 2015 Mar; 21(6):1497. PubMed ID: 25770295 [No Abstract] [Full Text] [Related]
3. Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. Yu KH; Ricigliano M; Hidalgo M; Abou-Alfa GK; Lowery MA; Saltz LB; Crotty JF; Gary K; Cooper B; Lapidus R; Sadowska M; O'Reilly EM Clin Cancer Res; 2014 Oct; 20(20):5281-9. PubMed ID: 25107917 [TBL] [Abstract][Full Text] [Related]
4. [Pancreatic cancer: a major challenge in oncology]. Fölsch UR; Schäfer H Med Klin (Munich); 2004 Apr; 99(4):183-4. PubMed ID: 15085287 [No Abstract] [Full Text] [Related]
5. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer. Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222 [TBL] [Abstract][Full Text] [Related]
6. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer. Xiong G; Feng M; Yang G; Zheng S; Song X; Cao Z; You L; Zheng L; Hu Y; Zhang T; Zhao Y Cancer Lett; 2017 Jul; 397():94-102. PubMed ID: 28254409 [TBL] [Abstract][Full Text] [Related]
7. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. El Maalouf G; Le Tourneau C; Batty GN; Faivre S; Raymond E Cancer Treat Rev; 2009 Apr; 35(2):167-74. PubMed ID: 19027240 [TBL] [Abstract][Full Text] [Related]
9. Monitoring and Characterization of Circulating Tumor Cells (CTCs) in a Patient With EML4-ALK-Positive Non-Small Cell Lung Cancer (NSCLC). Aieta M; Facchinetti A; De Faveri S; Manicone M; Tartarone A; Possidente L; Lerose R; Mambella G; Calderone G; Zamarchi R; Rossi E Clin Lung Cancer; 2016 Sep; 17(5):e173-e177. PubMed ID: 27397482 [No Abstract] [Full Text] [Related]
10. Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors. Gilbert JA; Lloyd RV; Ames MM N Engl J Med; 2005 Jul; 353(2):209-10. PubMed ID: 16014895 [No Abstract] [Full Text] [Related]
11. Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. Kang SP; Saif MW JOP; 2008 May; 9(3):251-66. PubMed ID: 18469437 [TBL] [Abstract][Full Text] [Related]
12. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Noma B; Sasaki T; Fujimoto Y; Serikawa M; Kobayashi K; Inoue M; Itsuki H; Kamigaki M; Minami T; Chayama K Int J Oncol; 2008 Dec; 33(6):1187-94. PubMed ID: 19020751 [TBL] [Abstract][Full Text] [Related]
13. Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment. Fitzgerald TL; McCubrey JA Adv Biol Regul; 2014 Sep; 56():45-50. PubMed ID: 24925031 [TBL] [Abstract][Full Text] [Related]
14. Upregulation of cugbp2 increases response of pancreatic cancer cells to chemotherapy. Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Dauksa A; Paskauskas S; Gulbinas A; Dambrauskas Z Langenbecks Arch Surg; 2016 Feb; 401(1):99-111. PubMed ID: 26691217 [TBL] [Abstract][Full Text] [Related]
19. CANCER. Cancer therapies that are gone with the Wnt. Nanus DM; Giannakakou P Science; 2015 Sep; 349(6254):1283-4. PubMed ID: 26383936 [No Abstract] [Full Text] [Related]
20. Pharmacogenetics and other molecular targets in the management of pancreatic adenocarcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. Merika E; Syrigos KN; Saif MW JOP; 2010 Jul; 11(4):328-30. PubMed ID: 20601804 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]